Literature DB >> 12738374

Differential expression of IFN-alpha subtypes in human PBMC: evaluation of novel real-time PCR assays.

S Löseke1, E Grage-Griebenow, A Wagner, K Gehlhar, A Bufe.   

Abstract

Studies of the human IFN-alpha subtype system have been hampered by the lack of efficient procedures to quantify and differentiate the expression of the highly homologous IFN-alpha subtypes. Here we evaluate four novel real-time PCR assays for the specific detection and quantification of IFN-alpha mRNA for the subtypes alpha(2), alpha(6), alpha(8) and alpha(1/13) in a combined assay in human peripheral blood mononuclear cells (PBMC). This included (a) the selection of beta-glucuronidase (GUS) as a suitable housekeeping gene for relative quantification; (b) verification of the specificity by using human DNA of different IFN-alpha subtypes; and (c) comparison of the amplification efficiencies among the different assays. This highly sensitive method allows the detection of low-level, constitutive IFN-alpha mRNA and shows differences in the composition of constitutive IFN-alpha subtypes compared to other cell types (HeLa and HEp-2). The in vitro stimulation of PBMC with Newcastle disease virus (NDV), Respiratory syncytial virus (RSV) or an inactivated Herpes simplex (HSV) preparation leads to the transcriptional induction of all IFN-alpha subtypes investigated but to different expression levels. Among the subtypes detected, IFN-alpha(13/1) and alpha(2) are the major transcripts followed by alpha(8), and finally alpha(6) as a minor transcribed subtype. Time-kinetics of IFN-alpha transcriptional activation also revealed variations in the course of IFN-alpha transcription between NDV, RSV or HSV. The data obtained from the real-time PCR assays correlated well with IFN-alpha(2) protein release. In conclusion, we have demonstrated the suitability and reliability of new real-time PCR assays for the rapid and efficient analysis of IFN-alpha subtype expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738374     DOI: 10.1016/s0022-1759(03)00072-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  24 in total

1.  Induction of IFN-α subtypes and their antiviral activity in mumps virus infection.

Authors:  Maja Markušić; Maja Šantak; Tanja Košutić-Gulija; Mladen Jergović; Renata Jug; Dubravko Forčić
Journal:  Viral Immunol       Date:  2014-12       Impact factor: 2.257

2.  Rigid interferon-alpha subtype responses of human plasmacytoid dendritic cells.

Authors:  Richard Szubin; W L William Chang; Tamara Greasby; Laurel Beckett; Nicole Baumgarth
Journal:  J Interferon Cytokine Res       Date:  2008-12       Impact factor: 2.607

3.  The DNA damage response induces IFN.

Authors:  Sabrina Brzostek-Racine; Chris Gordon; Sarah Van Scoy; Nancy C Reich
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

4.  Multifaceted activities of type I interferon are revealed by a receptor antagonist.

Authors:  Doron Levin; William M Schneider; Hans-Heinrich Hoffmann; Ganit Yarden; Alberto Giovanni Busetto; Ohad Manor; Nanaocha Sharma; Charles M Rice; Gideon Schreiber
Journal:  Sci Signal       Date:  2014-05-27       Impact factor: 8.192

5.  Role of Leptin and SOCS3 in Inhibiting the Type I Interferon Response During Obesity.

Authors:  Elí Terán-Cabanillas; Jesús Hernández
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

6.  Engineering oncolytic measles virus to circumvent the intracellular innate immune response.

Authors:  Iana Haralambieva; Ianko Iankov; Kosei Hasegawa; Mary Harvey; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2007-01-16       Impact factor: 11.454

7.  The early interferon alpha subtype response in infant macaques infected orally with SIV.

Authors:  Juliet Easlick; Richard Szubin; Samantha Lantz; Nicole Baumgarth; Kristina Abel
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

8.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

Review 9.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.

Authors:  Lianna Li; Barbara Sherry
Journal:  Virology       Date:  2009-11-06       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.